A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Clinical trial NCT06068465 · COMPLETED
Trial details
- NCT number
- NCT06068465
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-27
- Primary completion
- 2026-02-01
- Enrollment
- 248
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.